久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

AztraZeneca to launch oncology drug Calquence in India

expresspharmaOctober 19, 2020

Tag: AztraZeneca , Acalabrutinib 100 mg capsules , Calquence , oncology drug

AstraZeneca Pharma India has received import and market permission in Form CT-20 (Marketing Authorization- Additional Indication) from the Drugs Controller General of India for Acalabrutinib 100 mg capsules (Calquence ). AstraZeneca Pharma India intends to launch Calquence in India on October 21, 2020.

Acalabrutinib 100 mg capsules (Calquence ) is:

  • Indicated for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

  • Indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL).


Previous:Vaccine trials outside home market will help Chinese firms capture Asia, South and Central America markets: GlobalData

Next:US FDA approves Amantadine Hydrochloride Tablets, 100 mg from Alembic Pharma

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service